Eligibility for renal denervation: Experience at 11 European expert centers

Hypertension

Volumn 63, Issue 6, 2014, Pages 1319-1325

  Persu, Alexandre ^a,b   Jin, Yu ^c   Baelen, Marie ^b   Vink, Eva ^d   Verloop, Willemien L ^d   Schmidt, Bernhard ^e   Blicher, Marie K ^f   Severino, Francesca ^b   Wuerzner, Grégoire ^g   Taylor, Alison ^h   Pechère Bertschi, Antoinette ⁱ   Jokhaji, Fadi ^j   Elmula, Fadl Elmula M Fadl ^k   Rosa, Jan ^l   Czarnecka, Danuta ^m   Ehret, Georg ⁱ   Kahan, Thomas ^j   Renkin, Jean ^a,b   Widimský Jr , Jiří ^l   Jacobs, Lotte ^c   Spiering, Wilko ^d   Burnier, Michel ^g   Mark, Patrick B ^h   Menne, Jan ^e   Olsen, Michael H ^f   Blankestijn, Peter J ^d   Kjeldsen, Sverre ^k   Bots, Michiel L ^d   Staessen, Jan A ^c   more..

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^j Sweden Karolinska Institutet Department of Clinical Sciences Danderyd Hospital Stressrehab FoU Danderyd   (Sweden)

^k ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^l CHARLES UNIVERSITY   (Czech Republic)

^m JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

more..

Author keywords

Antihypertensive Agents; Hypertension Resistant to Conventional Therapy; Sympathetic Denervation

Indexed keywords

ANTIHYPERTENSIVE AGENT; SPIRONOLACTONE; VASCULOTROPIN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOLOGIST; CERTIFICATION; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CENTER; HUMAN; HYPERCORTISOLISM; HYPERTENSION; KIDNEY ARTERY STENOSIS; KIDNEY DENERVATION; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MULTICENTER STUDY; NEPHROLOGIST; PATIENT SELECTION; PERSONAL EXPERIENCE; PRESCRIPTION; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; SCREENING TEST; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; HYPERTENSION RESISTANT TO CONVENTIONAL THERAPY; SYMPATHETIC DENERVATION;

AGED; EUROPE; FEMALE; HUMANS; HYPERTENSION; KIDNEY; LOGISTIC MODELS; MALE; MIDDLE AGED; REFERRAL AND CONSULTATION; SYMPATHECTOMY;

EID: 84902246226     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03194     Document Type: Article

References (30)

1. Staessen JA, Kuznetsova T, Stolarz K. Hypertension prevalence and stroke mortality across populations. JAMA. 2003;289:2420-2422.
2. Hayek SS, Abdou MH, Demoss BD, Legaspi JM, Veledar E, Deka A, Krishnan SK, Wilmot KA, Patel AD, Kumar VR, Devireddy CM. Prevalence of resistant hypertension and eligibility for catheter-based renal denervation in hypertensive outpatients. Am J Hypertens. 2013;26: 1452-1458.
3. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheterbased renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-1281.
4. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-1909.
5. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension. Durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-917.
6. Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension. 2012;60:596-606.
7. Persu A, Renkin J, Asayama K, O'Brien E, Staessen JA. Renal denervation in treatment-resistant hypertension: the need for restraint and more and better evidence. Expert Rev Cardiovasc Ther. 2013;11:739-749.
8. Persu A, Jin Y, Azizi M, et al. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014;28:150-156.
9. Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132-140.
10. Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report. Heart. 2013;99:1579-1587.
11. Vonend O, Antoch G, Rump LC, Blondin D. Secondary rise in blood pressure after renal denervation. Lancet. 2012;380:778.
12. Kaltenbach B, Id D, Franke JC, Sievert H, Hennersdorf M, Maier J, Bertog SC. Renal artery stenosis after renal sympathetic denervation. J Am Coll Cardiol. 2012;60:2694-2695.
13. Templin C, Jaguszewski M, Ghadri JR, Sudano I, Gaehwiler R, Hellermann JP, Schoenenberger-Berzins R, Landmesser U, Erne P, Noll G, Lüscher TF. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity catheter system and the EnligHTN multi-electrode renal denervation catheter. Eur Heart J. 2013;34:2141-2148, 2148b.
14. Petidis K, Anyfanti P, Doumas M. Renal sympathetic denervation: renal function concerns. Hypertension. 2011;58:1-19.
15. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34:2132-2140.
16. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Ruilope L, van de Borne P, Tsioufis C. ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens. 2012;30:837-841.
17. Mahfoud F, Lüscher TF, Andersson B, et al; European Society of Cardiology. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013;34:2149-2157.
18. Verloop WL, Vink EE, Voskuil M, Vonken EJ, Rookmaaker MB, Bots ML, Doevendans PA, Blankestijn PJ, Spiering W. Eligibility for percutaneous renal denervation: the importance of a systematic screening. J Hypertens. 2013;31:1662-1668.
19. Savard S, Frank M, Bobrie G, Plouin PF, Sapoval M, Azizi M. Eligibility for renal denervation in patients with resistant hypertension: when enthusiasm meets reality in real-life patients. J Am Coll Cardiol. 2012;60:2422-2424.
20. Fadl Elmula FE, Hoffmann P, Fossum E, Brekke M, Gjønnæss E, Hjørnholm U, Kjær VN, Rostrup M, Kjeldsen SE, Os I, Stenehjem AE, Høieggen A. Renal sympathetic denervation in patients with treatmentresistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62:526-532.
21. Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, Laurent S, Menard J, Plouin PF. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens. 2012;30:1656-1664.
22. Brandt MC, Reda S, Mahfoud F, Lenski M, Böhm M, Hoppe UC. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol. 2012;60:1956-1965.
23. Hanselin MR, Saseen JJ, Allen RR, Marrs JC, Nair KV. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension. 2011;58:1008-1013.
24. Mann JF, Schmieder RE, McQueen M, et al; ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-553.
25. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367: 2204-2213.
26. Václavík J, Sedlák R, Plachy M, Navrátil K, Plásek J, Jarkovsky J, Václavík T, Husár R, Kociánová E, Táborsky M. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069-1075.
27. Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013;31:2094-2102.
28. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:889-890.
29. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LKG, Amaro ACS, Amodeo C, Bortolotto LA, Krieger EM, Bradley TD, Lorenzi-Filho G. The most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58:811-817.
30. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012;35:528-535.